Autophagy addiction underlying the primaryresistance of HER2 gene-amplified breast cancer cells to HER1/2 targeting therapies may depend, atleast in part, on the previously unrecognized ability of autophagy to regulate atrastuzumab-unresponsive CD44+CD24−/low mesenchymal cellular state. The gene discussed is ERBB2; the disease is breast carcinoma.